.infobox .infobox-protein
!!! Info
- Protein Name: Platelet-Derived Growth Factor Subunit A (PDGF-A)
- Gene: PDGFA
- UniProt: P16234
- Primary Receptor Bias: PDGFRA homodimer signaling
- Subcellular Localization: Secreted extracellular growth factor
- Functional Axis: OPC biology, white-matter repair, neurovascular support
PDGF-A is a secreted growth-factor subunit in the PDGF family that usually acts as a disulfide-linked PDGF-AA homodimer.[1] In brain and spinal cord biology, PDGF-A is best known for maintaining oligodendrocyte precursor cell (OPC) pools, regulating myelination dynamics, and supporting remyelination responses after injury.[2][3] Because white-matter failure, glial dysfunction, and vascular stress are recurring themes across Alzheimer's disease, Parkinson's disease, and atypical parkinsonian syndromes, PDGF-A is increasingly treated as a systems-level repair signal rather than only a developmental mitogen.[4][5]
PDGF-A is synthesized as a preproprotein that is proteolytically processed and secreted as a cystine-knot growth factor.[1:1] The mature ligand forms PDGF-AA homodimers and can also form PDGF-AB heterodimers with PDGF-B.[1:2] Compared with PDGF-BB, PDGF-AA has stronger functional coupling to PDGFRA-driven programs in glial progenitors and white-matter lineage cells, while showing less pericyte-focused signaling bias.[2:1][6]
In translational CNS work, this ligand-selectivity matters: investigators using PDGF-AA are often prioritizing oligodendroglial regeneration and synaptic-metabolic support, while PDGF-BB programs often target blood-brain barrier and pericyte biology through PDGFR-Beta Protein.[4:1][5:1]
Classic and modern studies show PDGF signaling is a major regulator of OPC abundance and turnover in both development and adult CNS tissue.[2:2][3:1] In demyelination paradigms, PDGF-driven signaling supports expansion of progenitors that later differentiate into myelinating oligodendrocytes, shaping lesion repair capacity.[2:3]
White-matter vulnerability is a convergent mechanism across neurodegenerative disorders with gait and executive dysfunction phenotypes. PDGF-A signaling helps preserve the precursor reservoir required for remyelination after inflammatory, ischemic, or toxic stress.[2:4][7] This links PDGF-A to clinically relevant trajectories in disorders where conduction failure and network disconnection amplify cognitive or motor decline.
By sustaining oligodendroglial lineage cells and glial metabolic support programs, PDGF-A may indirectly buffer axonal energy stress and synaptic instability, two processes central to progressive degeneration.[3:2][8]
In AD-spectrum disease, white-matter damage and neurovascular dysfunction are tightly coupled. Although PDGF-B/PDGFRB markers are currently the most mature vascular readouts, PDGF-A remains mechanistically relevant where oligodendroglial failure coexists with vascular injury.[4:2][5:2][9] A practical interpretation is that PDGF-A biology may best serve combination strategies that target both myelin lineage repair and barrier stabilization.
PDGF-focused work in PD has emphasized PDGF-BB in early clinical translation, but the broader pathway logic is relevant to PDGF-A as well: trophic support, anti-degenerative signaling, and repair-permissive glial states.[10][11] In PD or CBS/PSP settings with white-matter involvement, PDGF-A hypotheses are biologically plausible but remain under-tested in controlled human studies.
Because PDGF-A is deeply linked to OPC kinetics, it is especially relevant in phenotypes where demyelination/remyelination mismatch drives disability progression.[2:5][7:1] This includes mixed neuroinflammatory-neurodegenerative states where preserving precursor pools may alter long-term network failure.
Exogenous PDGF-AA has conceptual appeal for remyelination programs, but durable benefit likely depends on timing, differentiation context, and co-control of inflammatory barriers that otherwise trap OPCs in a proliferative but non-remyelinating state.[2:6][7:2]
Instead of direct ligand delivery, pathway-supportive strategies can target downstream survival/metabolic nodes that preserve oligodendroglial competence under chronic stress. This approach may reduce receptor overactivation risks while still leveraging PDGF-A biology.[3:3][8:1]
For neurodegenerative disease, the strongest design pattern is pairing myelin-lineage support (PDGF-A axis) with neurovascular stabilization (PDGF-B/PDGFRB axis), then layering disease-specific anti-proteinopathy interventions.[4:3][5:3][9:1]
PDGF pathways are pleiotropic and pro-proliferative. Any sustained activation strategy needs dose discipline, target engagement biomarkers, and oncology-aware safety monitoring, especially in older adults with multimorbidity.[1:3][10:1] For CNS work, over-proliferation without functional differentiation is a specific risk in remyelination-focused paradigms.[2:7]
Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes & Development. 2008. ↩︎ ↩︎ ↩︎ ↩︎
Woodruff RH, Fruttiger M, Richardson WD, Franklin RJM. Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Molecular and Cellular Neurosciences. 2004. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Hill RA, Nishiyama A. NG2 cells in white matter but not gray matter proliferate in response to PDGF. The Journal of Neuroscience. 2014. ↩︎ ↩︎ ↩︎ ↩︎
Bell RD, Winkler EA, Sagare AP, et al. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010. ↩︎ ↩︎ ↩︎ ↩︎
Bell RD, Winkler EA, Singh I, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020. ↩︎ ↩︎ ↩︎ ↩︎
Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine & Growth Factor Reviews. 2004. ↩︎
Mitew S, Hay CM, Peckham H, et al. Mechanisms regulating the development of oligodendrocytes and central nervous system myelin. Neuroscience. 2014. ↩︎ ↩︎ ↩︎
Saab AS, Nave KA. Myelin dynamics and neurodegeneration. Current Opinion in Neurobiology. 2017. ↩︎ ↩︎
Nation DA, Sweeney MD, Montagne A, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nature Medicine. 2019. ↩︎ ↩︎
Paul G, Zachrisson O, Varrone A, et al. Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients. Journal of Clinical Investigation. 2015. ↩︎ ↩︎
Paul G, Sullivan AM. Trophic factors for Parkinson's disease: Where are we and where do we go from here?. European Journal of Neuroscience. 2019. ↩︎